Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Jun '17
Piotroski F-Score
6 4 3 2 3 4 4 — — —
P/E ratio
5.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(1.06) (4.57) (7.29) (3.10) 11.97 9.29 (5.09) (5.27) (30.97) (6.02)
P/S ratio
0.34 4.65 11.97 315.02 853.72 124.61 0.77 2.86 2.68 0.12
Altman Z″-Score (non-manufacturers)
(4.73) (12.33) (16.58) (5.78) 5.11 4.95 (11.08) (11.39) (74.58) (11.45)
P/FCF ratio
10.64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
3.73 (1.09) 58.85 (4.48) (4.03) (4.85) (2.02) 24.45 — —
P/Operating CF
2.63 (18.16) (6.53) (4.12) (48.15) (46.83) (1.99) (2.08) (14.81) (0.57)
P/B ratio
0.92 2.26 1.53 1.09 4.06 4.09 0.58 1.06 0.00 0.05
Price to Tangible BV
1.00 2.62 1.80 1.19 4.42 4.67 0.00 0.00 0.00 0.05
EV/Sales
0.08 2.89 6.75 66.88 668.39 93.54 (0.49) 0.56 7.28 (4.65)
EV/EBITDA
0.68 0.00 0.00 0.00 0.00 0.00 0.39 0.00 0.00 3.45
EV/Operating CF
2.33 (1.85) (0.71) (0.27) (9.96) (15.94) 0.37 (0.16) (6.15) 1.46
EV/FCF
2.37 (1.83) (0.69) (0.24) (9.17) (15.16) 0.34 (0.15) (6.12) 1.46
Quick Ratio
1.33 0.70 3.11 5.34 15.45 10.81 1.87 1.78 0.80 6.64
Current Ratio
1.57 0.75 3.32 5.55 15.69 10.93 1.92 1.96 0.83 6.76
Net Debt/EBITDA
(2.42) 0.89 0.53 0.88 2.43 4.62 1.11 0.52 (3.77) 1.41
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.52% 856.11% 0.25%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.17 (1.00) 0.01
Asset Turnover
1.35 0.22 0.06 0.00 0.00 0.04 0.27 0.21 0.26 0.16
Operating CF/Net income
0.47 0.67 0.85 0.88 0.85 0.74 0.70 0.79 0.81 1.02
Capex/Depreciation
(0.02) (0.07) (0.22) (1.70) (1.20) (0.45) (0.24) (0.22) (0.09) 0.00
Interest Coverage
6.40 (22.33) (57.60) (87.81) (49.16) (16.10) (6.61) (8.12) (3.30) (15.28)
ROE
22.26% (114.71%) (97.94%) (72.29%) (45.33%) (47.26%) (154.15%) 133.50% 124.46% (90.60%)
ROA
9.26% (51.85%) (67.13%) (57.47%) (37.71%) (33.98%) (51.61%) (92.31%) (55.85%) (52.13%)
ROIC
47.09% (575.30%) (287.93%) (481.30%) (216.07%) 0.00% 0.00% (811.31%) 0.00% 0.00%
Return on Tangible Assets
29.79% 481.19% (189.39%) (110.96%) (42.71%) (27.25%) (215.95%) (222.75%) 31,150.00% (85.96%)
Average Days of Receivables
78.99 152.22 148.79 68.22 29.05 30.13 133.94 157.62 39.38 24.61
Research and Development Expense of Revenue
84.96% 258.58% 923.46% 75,751.40% 5,465.13% 490.93% 147.43% 415.36% 211.59% 317.98%
Selling, General and Administrative Expense of Revenue
7.42% 72.40% 306.06% 27,463.55% 2,454.04% 375.73% 62.74% 160.64% 59.92% 89.89%
Intangible Assets out of Total Assets
0.04 0.05 0.10 0.06 0.07 0.10 0.46 0.55 0.01 0.00
Share Based Compensation of Revenue
3.50% 40.07% 191.52% 12,698.13% 994.06% 107.71% 6.36% 12.96% 8.17% 21.35%
Graham Net Nets
0.47 (0.29) 0.13 0.47 0.18 0.20 (0.86) (0.79) (1.89) 18.50
Graham Number
0.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 36.56 0.00
Earnings Yield
17.14% (51.52%) (95.08%) (89.36%) (9.25%) (6.13%) (291.43%) (122.87%) (90.75%) (113.45%)
Free Cash Flow Yield
9.40% (33.97%) (81.73%) (86.97%) (8.53%) (4.95%) (184.65%) (128.47%) (44.31%) (2,561.52%)
Revenue per Share
1.03 0.14 0.05 0.00 0.01 0.05 0.46 0.66 42.93 2.53
Operating CF per Share
0.03 (0.22) (0.49) (0.74) (0.49) (0.27) (0.61) (2.30) (73.82) (8.54)
Capex per Share
0.00 0.00 (0.01) (0.08) (0.04) (0.01) (0.04) (0.11) (0.35) 0.00
Free Cash Flow per Share
0.03 (0.22) (0.50) (0.82) (0.54) (0.28) (0.65) (2.42) (74.17) (8.54)
Cash per Share
0.28 0.26 0.27 0.75 1.37 1.44 0.63 1.82 21.96 10.99
Shareholders Equity per Share
0.38 0.29 0.40 0.87 1.54 1.40 0.60 1.78 (284.72) 5.32
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.38 0.29 0.40 0.87 1.54 1.40 0.60 1.78 (284.72) 5.32
Free Cash Flow
7.57 (45.32) (72.20) (104.38) (64.99) (24.97) (13.94) (15.25) (10.09) (30.00)
Working Capital
49.37 (22.62) 31.81 81.53 158.38 116.77 8.42 7.17 (0.77) 34.00
Capital Expenditures
(0.14) (0.55) (1.75) (9.60) (5.16) (1.22) (0.85) (0.71) (0.05) —
Net Current Asset Value
37.84 (39.20) 11.51 56.20 135.53 99.35 (6.48) (9.34) (39.49) 18.50
EV/EBIT
0.99 0.00 0.00 0.00 0.00 0.00 0.30 0.00 0.00 1.86
Capex to Sales
0.00 0.02 0.24 89.73 5.78 0.30 0.09 0.17 0.01 0.00
Price to Operating Income
4.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
1.53 0.93 0.68 0.36 0.65 1.83 17.12 3.02 0.75 0.50
Cash ROIC
5.00% (40.96%) (74.04%) (50.59%) (18.36%) (9.98%) (52.65%) (61.79%) (337.81%) (52.26%)
Accounts Receivable Turnover
7.49 3.83 4.87 2.35 4.40 2.05 3.64 3.43 9.49 13.69
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 — — — — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 — — — — — —
Average Receivables
31.66 7.49 1.51 0.05 0.20 1.98 2.71 1.21 0.62 0.65
Average Payables
14.23 4.27 3.55 4.69 3.00 1.49 0.91 1.18 1.40 2.65
Average Assets
176.23 129.11 122.84 187.51 186.88 94.81 36.13 19.88 22.31 56.40
Average Common Equity
73.36 58.37 84.20 149.06 155.47 68.18 12.10 (13.74) (10.01) 32.45

Fold the line items

Columns are period end dates